64.92

0.87% -0.57

Bio Techne Corp (TECH)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$65.49

Offen:

$66.21

24-Stunden-Volumen:

1.94M

Relative Volume:

1.79

Marktkapitalisierung:

$10.26B

Einnahmen:

$1.17B

Nettoeinkommen (Verlust:

$150.71M

KGV:

69.06

EPS:

0.94

Netto-Cashflow:

$245.03M

1W Leistung:

-1.55%

1M Leistung:

-17.56%

6M Leistung:

-10.64%

1J Leistung:

-9.48%

1-Tages-Spanne:

$64.58

$66.87

1-Wochen-Bereich:

$63.51

$67.19

52-Wochen-Spanne:

$61.16

$85.57

Bio Techne Corp Stock (TECH) Company Profile

Firmenname

Bio Techne Corp

Sektor

Healthcare (1169)

Branche

Biotechnology (678)

Telefon

(612) 379-8854

Adresse

614 MCKINLEY PL N E, MINNEAPOLIS, MN

Mitarbeiter

3,100

Twitter

@biotechne

Nächster Verdiensttermin

2024-10-30

Neueste SEC-Einreichungen

TECH's Discussions on Twitter

Vergleichen Sie TECH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TECH Bio Techne Corp	64.92	10.26B	1.17B	150.71M	245.03M	0.94
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Bio Techne Corp Stock (TECH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-19	Herabstufung	Robert W. Baird	Outperform → Neutral
2024-05-22	Herabstufung	Citigroup	Buy → Neutral
2024-02-08	Eingeleitet	Scotiabank	Sector Outperform
2024-02-02	Herabstufung	Stifel	Buy → Hold
2023-12-07	Eingeleitet	UBS	Buy
2023-08-28	Eingeleitet	William Blair	Outperform
2023-01-10	Hochstufung	Wells Fargo	Underweight → Equal Weight
2022-12-14	Eingeleitet	Deutsche Bank	Buy
2022-12-12	Hochstufung	Citigroup	Neutral → Buy
2022-12-07	Eingeleitet	RBC Capital Mkts	Sector Perform
2022-08-25	Eingeleitet	Credit Suisse	Outperform
2022-04-25	Herabstufung	Wells Fargo	Equal Weight → Underweight
2021-09-15	Hochstufung	KeyBanc Capital Markets	Sector Weight → Overweight
2021-03-08	Hochstufung	Stephens	Equal-Weight → Overweight
2021-02-23	Hochstufung	Stifel	Hold → Buy
2021-01-25	Bestätigt	The Benchmark Company	Buy
2020-11-10	Eingeleitet	KeyBanc Capital Markets	Sector Weight
2020-09-30	Eingeleitet	Atlantic Equities	Overweight
2020-07-15	Herabstufung	Stephens	Overweight → Equal-Weight
2020-05-27	Herabstufung	Stifel	Buy → Hold
2020-05-14	Eingeleitet	The Benchmark Company	Buy
2020-01-08	Fortgesetzt	Stephens	Overweight
2020-01-08	Eingeleitet	Wells Fargo	Equal Weight
2020-01-07	Eingeleitet	Citigroup	Neutral
2019-11-15	Eingeleitet	Stifel	Buy
2019-07-02	Hochstufung	Janney	Neutral → Buy
2019-01-14	Hochstufung	Stephens	Equal-Weight → Overweight
2018-10-31	Herabstufung	Craig Hallum	Buy → Hold
2018-10-17	Eingeleitet	Goldman	Neutral
2018-06-15	Eingeleitet	Argus	Buy
2017-07-13	Eingeleitet	Wells Fargo	Market Perform
2017-02-09	Eingeleitet	Citigroup	Buy
2017-01-18	Eingeleitet	Deutsche Bank	Buy
2016-11-10	Fortgesetzt	Leerink Partners	Outperform
2015-01-21	Bestätigt	Robert W. Baird	Outperform
2013-09-20	Hochstufung	Robert W. Baird	Neutral → Outperform

Alle ansehen

Bio Techne Corp Aktie (TECH) Neueste Nachrichten

Feb 20, 2025

Bio-Techne Expands RNAscope Probes For Human And Mouse Transcriptome In Spatial Biology - Nasdaq

Feb 20, 2025

Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology - Quantisnow

Feb 20, 2025

Feb 19, 2025

Deep Dive Into Bio-Techne Stock: Analyst Perspectives (4 Ratings) - Benzinga

Feb 19, 2025

Bio-Techne downgraded to Neutral from Outperform at Baird - TipRanks

Feb 19, 2025

Bio-Techne launches GMP TcBuster for cell therapy development By Investing.com - Investing.com Nigeria

Feb 19, 2025

Feb 18, 2025

Bio-Techne director Amy Herr sells $122,690 in stock By Investing.com - Investing.com Nigeria

Feb 18, 2025

Bio-Techne's (NASDAQ:TECH) Soft Earnings Don't Show The Whole Picture - Yahoo Finance

Feb 18, 2025

Bio-Techne launches GMP TcBuster for cell therapy development - Investing.com India

Feb 18, 2025

Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System - Yahoo Finance

Feb 18, 2025

Feb 14, 2025

Mirae Asset Global Investments Co. Ltd. Increases Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat

Feb 14, 2025

Earnings call transcript: Bio-Techne Q4 2024 beats EPS forecast By Investing.com - Investing.com Nigeria

Feb 14, 2025

Allspring Global Investments Holdings LLC Has $52.64 Million Stake in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat

Feb 14, 2025

Q4 Earnings Estimate for Bio-Techne Issued By William Blair - MarketBeat

Feb 14, 2025

Earnings call transcript: Bio-Techne Q4 2024 beats EPS forecast - Investing.com

Feb 14, 2025

Q4 EPS Estimates for Bio-Techne Decreased by Leerink Partnrs - MarketBeat

Feb 14, 2025

Feb 13, 2025

Bio-Techne (NASDAQ:TECH) Shares Gap DownHere's What Happened - MarketBeat

Feb 13, 2025

Brokerages Set Bio-Techne Co. (NASDAQ:TECH) Price Target at $86.57 - MarketBeat

Feb 13, 2025

4,474 Shares in Bio-Techne Co. (NASDAQ:TECH) Bought by Summit Trail Advisors LLC - MarketBeat

Feb 13, 2025

Bio-Techne Co. (NASDAQ:TECH) Position Reduced by State of Alaska Department of Revenue - MarketBeat

Feb 13, 2025

Feb 12, 2025

Stephens Investment Management Group LLC Has $52.92 Million Stock Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat

Feb 12, 2025

Bio-Techne Corporation: How Spatial Biology and Molecular Diagnostics Are Changing the Game! - Smartkarma

Feb 12, 2025

Ex-Dividend Reminder: Cencora, Bio-Techne and Eli Lilly - Nasdaq

Feb 12, 2025

Bio-Techne Corp. stock underperforms Monday when compared to competitors - MSN

Feb 12, 2025

Bio-Techne Co. (NASDAQ:TECH) Shares Acquired by Sumitomo Mitsui Trust Group Inc. - MarketBeat

Feb 12, 2025

Feb 10, 2025

Bio-Techne (NASDAQ:TECH) Price Target Raised to $90.00 - MarketBeat

Feb 10, 2025

Bio-Techne (NASDAQ:TECH) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat

Feb 10, 2025

Feb 09, 2025

Bio-Techne (NASDAQ:TECH) Shares Gap Up After Dividend Announcement - MarketBeat

Feb 09, 2025

Feb 08, 2025

TECH Gears Up to Report Q2 Earnings: Here's What to Expect - MSN

Feb 08, 2025

KeyCorp Issues Positive Forecast for Bio-Techne (NASDAQ:TECH) Stock Price - MarketBeat

Feb 08, 2025

Bio-Techne (NASDAQ:TECH) Given New $80.00 Price Target at Royal Bank of Canada - MarketBeat

Feb 08, 2025

Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Cor - GuruFocus.com

Feb 08, 2025

Feb 07, 2025

Trust Point Inc. Buys 7,333 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat

Feb 07, 2025

Bio-Techne Corp. stock underperforms Friday when compared to competitors - MarketWatch

Feb 07, 2025

Bio-Techne Appoints Dr. Amy E. Herr as Independent Director and Announces DividendOn January 30, 2025, Bio-Techne Corporation (NASDAQ: TECH) took steps to enhance its Board of Directors with the appointment of Dr. Amy E. Herr as an independent di - Defense World

Feb 07, 2025

Feb 06, 2025

Conestoga Capital Advisors LLC Buys 5,025 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat

Feb 06, 2025